In today’s session Ophthotech Corp (OPHT) registered an unusually high (1,052) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious OPHT increase. With 1,052 contracts traded and 34814 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: OPHT170120C00070000 closed last at: $10 or 0% . About 534,230 shares traded hands. Ophthotech Corp (NASDAQ:OPHT) has declined 12.01% since March 14, 2016 and is downtrending. It has underperformed by 17.62% the S&P500.
Analysts await Ophthotech Corp (NASDAQ:OPHT) to report earnings on November, 3. They expect $-1.59 earnings per share, down 39.47% or $0.45 from last year’s $-1.14 per share. After $-0.85 actual earnings per share reported by Ophthotech Corp for the previous quarter, Wall Street now forecasts 87.06% negative EPS growth.
Ophthotech Corp (NASDAQ:OPHT) Ratings Coverage
Out of 10 analysts covering Ophthotech Corporation (NASDAQ:OPHT), 9 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 90% are positive. Ophthotech Corporation has been the topic of 14 analyst reports since August 4, 2015 according to StockzIntelligence Inc. Barclays Capital initiated the shares of OPHT in a report on Wednesday, April 27 with “Overweight” rating. The stock of Ophthotech Corp (NASDAQ:OPHT) has “Sell” rating given on Friday, August 7 by Goldman Sachs. The stock has “Buy” rating given by Citigroup on Thursday, August 4. On Friday, January 8 the stock rating was initiated by Suntrust Robinson with “Buy”. Citigroup initiated Ophthotech Corp (NASDAQ:OPHT) on Thursday, September 3 with “Buy” rating. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, August 6. The stock of Ophthotech Corp (NASDAQ:OPHT) has “Buy” rating given on Tuesday, September 8 by Chardan Capital Markets. The stock of Ophthotech Corp (NASDAQ:OPHT) has “Buy” rating given on Thursday, January 7 by SunTrust. The stock of Ophthotech Corp (NASDAQ:OPHT) has “Overweight” rating given on Thursday, June 2 by JP Morgan. Chardan Capital Markets maintained Ophthotech Corp (NASDAQ:OPHT) rating on Monday, December 14. Chardan Capital Markets has “Buy” rating and $200 price target.
According to Zacks Investment Research, “Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered in New York.”
Insitutional Activity: The institutional sentiment increased to 1.95 in 2016 Q2. Its up 0.45, from 1.5 in 2016Q1. The ratio improved, as 21 funds sold all Ophthotech Corp shares owned while 34 reduced positions. 38 funds bought stakes while 69 increased positions. They now own 41.31 million shares or 29.52% more from 31.90 million shares in 2016Q1.
Guggenheim Capital Limited Liability Corp, a Illinois-based fund reported 55,222 shares. Jpmorgan Chase holds 92,581 shares or 0% of its portfolio. Quantitative Invest Limited Com accumulated 0.02% or 6,700 shares. Parametric Port Assoc Limited Liability Corporation has 0% invested in the company for 12,097 shares. Wellington Gru Llp has 336,066 shares for 0% of their US portfolio. Moreover, National Bank Of America De has 0% invested in Ophthotech Corp (NASDAQ:OPHT) for 234,439 shares. New York State Common Retirement Fund last reported 0.01% of its portfolio in the stock. Swiss Bancorp owns 42,088 shares or 0% of their US portfolio. Opaleye Mgmt Incorporated last reported 3.51% of its portfolio in the stock. Tocqueville Asset Management L P accumulated 0.05% or 69,690 shares. Pura Vida Invs Lc, a New York-based fund reported 52,500 shares. Goldman Sachs Gp last reported 0% of its portfolio in the stock. Silvercrest Asset Management Grp Ltd Liability Corporation reported 12,000 shares or 0.01% of all its holdings. Polar Cap Llp last reported 0.04% of its portfolio in the stock. Putnam Invs Ltd Liability has 0.01% invested in the company for 62,627 shares.
Insider Transactions: Since April 29, 2016, the stock had 1 buying transaction, and 14 selling transactions for $78.78 million net activity. $978,899 worth of shares were sold by GUYER DAVID R on Monday, October 3. On Thursday, September 29 PATEL SAMIR CHANDRAKANT sold $1.10M worth of the stock or 20,000 shares. $63.70 million worth of shares were sold by Novo A/S on Tuesday, May 24. 3,500 shares were bought by Bolte Axel, worth $199,395. SBLENDORIO GLENN sold 671 shares worth $38,381.
Ophthotech Corporation is a biopharmaceutical company. The company has a market cap of $1.34 billion. The Firm specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration . It currently has negative earnings. The Company’s advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.
OPHT Company Profile
Ophthotech Corporation, incorporated on January 5, 2007, is a biopharmaceutical company. The Firm specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). The Company’s advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV), a specific type of wet AMD. It is also investigating the potential of an ophthalmic formulation for tivozanib, a molecule VEGF tyrosine kinase inhibitor, for which the Company has an option for a license.
More recent Ophthotech Corp (NASDAQ:OPHT) news were published by: Fool.com which released: “Here’s Why Ophthotech Corporation Is Dropping Today” on September 30, 2016. Also Fool.com published the news titled: “Why Ophthotech Corp. Plunged 42% in March” on April 07, 2016. Fool.com‘s news article titled: “Why Ophthotech Corp. Shares Soared 14.9% in May” with publication date: June 09, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.